257 related articles for article (PubMed ID: 21873672)
1. Quantification of peripapillary sparing and macular involvement in Stargardt disease (STGD1).
Burke TR; Rhee DW; Smith RT; Tsang SH; Allikmets R; Chang S; Lazow MA; Hood DC; Greenstein VC
Invest Ophthalmol Vis Sci; 2011 Oct; 52(11):8006-15. PubMed ID: 21873672
[TBL] [Abstract][Full Text] [Related]
2. Foveal sparing in Stargardt disease.
van Huet RA; Bax NM; Westeneng-Van Haaften SC; Muhamad M; Zonneveld-Vrieling MN; Hoefsloot LH; Cremers FP; Boon CJ; Klevering BJ; Hoyng CB
Invest Ophthalmol Vis Sci; 2014 Oct; 55(11):7467-78. PubMed ID: 25324290
[TBL] [Abstract][Full Text] [Related]
3. Correlation between photoreceptor layer integrity and visual function in patients with Stargardt disease: implications for gene therapy.
Testa F; Rossi S; Sodi A; Passerini I; Di Iorio V; Della Corte M; Banfi S; Surace EM; Menchini U; Auricchio A; Simonelli F
Invest Ophthalmol Vis Sci; 2012 Jul; 53(8):4409-15. PubMed ID: 22661472
[TBL] [Abstract][Full Text] [Related]
4. Characterization of stargardt disease using polarization-sensitive optical coherence tomography and fundus autofluorescence imaging.
Ritter M; Zotter S; Schmidt WM; Bittner RE; Deak GG; Pircher M; Sacu S; Hitzenberger CK; Schmidt-Erfurth UM;
Invest Ophthalmol Vis Sci; 2013 Sep; 54(9):6416-25. PubMed ID: 23882696
[TBL] [Abstract][Full Text] [Related]
5. Multimodal imaging and multifocal electroretinography demonstrate autosomal recessive Stargardt disease may present like occult macular dystrophy.
Sisk RA; Leng T
Retina; 2014 Aug; 34(8):1567-75. PubMed ID: 24743636
[TBL] [Abstract][Full Text] [Related]
6. Disruption in Bruch membrane in patients with Stargardt disease.
Park SP; Chang S; Allikmets R; Smith RT; Burke TR; Gregory-Roberts E; Tsang SH
Ophthalmic Genet; 2012 Mar; 33(1):49-52. PubMed ID: 22060670
[TBL] [Abstract][Full Text] [Related]
7. Full-field ERG as a predictor of the natural course of
Schroeder M; Kjellström U
Mol Vis; 2018; 24():1-16. PubMed ID: 29386879
[TBL] [Abstract][Full Text] [Related]
8. Impact of segmentation density on spectral domain optical coherence tomography assessment in Stargardt disease.
Velaga SB; Nittala MG; Jenkins D; Melendez J; Ho A; Strauss RW; Scholl HP; Sadda SR
Graefes Arch Clin Exp Ophthalmol; 2019 Mar; 257(3):549-556. PubMed ID: 30613916
[TBL] [Abstract][Full Text] [Related]
9. Cone photoreceptor abnormalities correlate with vision loss in patients with Stargardt disease.
Chen Y; Ratnam K; Sundquist SM; Lujan B; Ayyagari R; Gudiseva VH; Roorda A; Duncan JL
Invest Ophthalmol Vis Sci; 2011 May; 52(6):3281-92. PubMed ID: 21296825
[TBL] [Abstract][Full Text] [Related]
10. Multimodal analysis of the Preferred Retinal Location and the Transition Zone in patients with Stargardt Disease.
Verdina T; Greenstein VC; Sodi A; Tsang SH; Burke TR; Passerini I; Allikmets R; Virgili G; Cavallini GM; Rizzo S
Graefes Arch Clin Exp Ophthalmol; 2017 Jul; 255(7):1307-1317. PubMed ID: 28365912
[TBL] [Abstract][Full Text] [Related]
11. The absence of fundus abnormalities in Stargardt disease.
Bax NM; Lambertus S; Cremers FPM; Klevering BJ; Hoyng CB
Graefes Arch Clin Exp Ophthalmol; 2019 Jun; 257(6):1147-1157. PubMed ID: 30903310
[TBL] [Abstract][Full Text] [Related]
12. Macular Sensitivity Measured With Microperimetry in Stargardt Disease in the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Study: Report No. 7.
Schönbach EM; Wolfson Y; Strauss RW; Ibrahim MA; Kong X; Muñoz B; Birch DG; Cideciyan AV; Hahn GA; Nittala M; Sunness JS; Sadda SR; West SK; Scholl HPN;
JAMA Ophthalmol; 2017 Jul; 135(7):696-703. PubMed ID: 28542693
[TBL] [Abstract][Full Text] [Related]
13. Loss of peripapillary sparing in non-group I Stargardt disease.
Burke TR; Allikmets R; Smith RT; Gouras P; Tsang SH
Exp Eye Res; 2010 Nov; 91(5):592-600. PubMed ID: 20696155
[TBL] [Abstract][Full Text] [Related]
14. Insights into autofluorescence patterns in Stargardt macular dystrophy using ultra-wide-field imaging.
Kumar V
Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):1917-1922. PubMed ID: 28689222
[TBL] [Abstract][Full Text] [Related]
15. A comparison of fundus autofluorescence and retinal structure in patients with Stargardt disease.
Gomes NL; Greenstein VC; Carlson JN; Tsang SH; Smith RT; Carr RE; Hood DC; Chang S
Invest Ophthalmol Vis Sci; 2009 Aug; 50(8):3953-9. PubMed ID: 19324865
[TBL] [Abstract][Full Text] [Related]
16. Clinical and genetic characteristics of late-onset Stargardt's disease.
Westeneng-van Haaften SC; Boon CJ; Cremers FP; Hoefsloot LH; den Hollander AI; Hoyng CB
Ophthalmology; 2012 Jun; 119(6):1199-210. PubMed ID: 22449572
[TBL] [Abstract][Full Text] [Related]
17. En Face Spectral-Domain Optical Coherence Tomography for the Monitoring of Lesion Area Progression in Stargardt Disease.
Melillo P; Testa F; Rossi S; Di Iorio V; Orrico A; Auricchio A; Simonelli F
Invest Ophthalmol Vis Sci; 2016 Jul; 57(9):OCT247-52. PubMed ID: 27409479
[TBL] [Abstract][Full Text] [Related]
18. Peripapillary Sparing With Near Infrared Autofluorescence Correlates With Electroretinographic Findings in Patients With Stargardt Disease.
Nassisi M; Mohand-Saïd S; Andrieu C; Antonio A; Condroyer C; Méjécase C; Dhaenens CM; Sahel JA; Zeitz C; Audo I
Invest Ophthalmol Vis Sci; 2019 Dec; 60(15):4951-4957. PubMed ID: 31790517
[TBL] [Abstract][Full Text] [Related]
19. The Rapid-Onset Chorioretinopathy Phenotype of ABCA4 Disease.
Tanaka K; Lee W; Zernant J; Schuerch K; Ciccone L; Tsang SH; Sparrow JR; Allikmets R
Ophthalmology; 2018 Jan; 125(1):89-99. PubMed ID: 28947085
[TBL] [Abstract][Full Text] [Related]
20. The Natural History of the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Studies: Design and Baseline Characteristics: ProgStar Report No. 1.
Strauss RW; Ho A; Muñoz B; Cideciyan AV; Sahel JA; Sunness JS; Birch DG; Bernstein PS; Michaelides M; Traboulsi EI; Zrenner E; Sadda S; Ervin AM; West S; Scholl HP;
Ophthalmology; 2016 Apr; 123(4):817-28. PubMed ID: 26786511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
